Division of Gastroenterology and Hepatology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Division of Rheumatology, Department of Internal Clinical Sciences, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Front Immunol. 2024 Jul 11;15:1411146. doi: 10.3389/fimmu.2024.1411146. eCollection 2024.
Mixed cryoglobulinemia vasculitis (MCV) is caused in ~90% of cases by chronic hepatitis C virus (HCVMCV) and more rarely by hepatitis B virus (HBV) infection, or apparently noninfectious. HCVMCV develops in only ~5% of patients with chronic hepatitis C (CHC), but risk factors other than female gender have not been identified so far. We conducted a retrospective case control study investigating whether past active HBV infection, defined by hepatitis B surface antigen (HBsAg) seroclearance and anti-core antibody (HBcAb) positivity, could be a risk factor for developing HCVMCV. The prevalence of HBsAg seroclearance was 48% within 123 HCVMCV patients and 29% within 257 CHC patients (p=0.0003). Multiple logistic regression including as variables gender, birth year, age at HBV testing, cirrhosis, and hepatocellular carcinoma, confirmed an association of HBsAg seroclearance with HCVMCV [adjusted odds ratio (OR) 2.82, 95% confidence interval (95% CI) 1.73-4.59, p<0.0001]. Stratification by gender, however, showed that HBsAg seroclearance was associated with HCVMCV in male [OR 4.63, 95% CI 2.27-9.48, p<0.0001] and not in female patients [OR 1.85, 95% 95% CI 0.94-3.66, p=0.076]. HBsAg seroclearance, and more likely occult HBV infection, is an independent risk factor for HCVMCV in male CHC patients.
混合性冷球蛋白血症性血管炎 (MCV) 在约 90%的病例中由慢性丙型肝炎病毒 (HCVMCV) 引起,在更罕见的情况下由乙型肝炎病毒 (HBV) 感染或明显非传染性因素引起。HCVMCV 仅在约 5%的慢性丙型肝炎 (CHC) 患者中发展,但迄今为止尚未确定除女性性别以外的其他危险因素。我们进行了一项回顾性病例对照研究,调查过去的乙型肝炎表面抗原 (HBsAg) 清除和抗核心抗体 (HBcAb) 阳性的乙型肝炎病毒既往感染是否可以成为发展为 HCVMCV 的危险因素。在 123 例 HCVMCV 患者中,HBsAg 清除率为 48%,在 257 例 CHC 患者中为 29%(p=0.0003)。包括性别、出生年份、HBV 检测时年龄、肝硬化和肝细胞癌在内的多变量逻辑回归证实,HBsAg 清除与 HCVMCV 相关[调整后的优势比 (OR) 2.82,95%置信区间 (95%CI) 1.73-4.59,p<0.0001]。然而,按性别分层显示,HBsAg 清除与男性 HCVMCV 相关[OR 4.63,95%CI 2.27-9.48,p<0.0001],而与女性患者无关[OR 1.85,95%CI 0.94-3.66,p=0.076]。HBsAg 清除,更可能是隐匿性乙型肝炎病毒感染,是男性 CHC 患者 HCVMCV 的独立危险因素。